Gilrose Pharmaceuticals
Developing novel therapies for diseases where the patient population is large, the suffering is great and for which there are currently no effective pharmaceutical remedies.
A Safe and Effective Treatment for Vast and Unserved Patient Populations.
Speech, language, gait and limb impairments are commonly found in people suffering from a range of neurological conditions.
Cerebral palsy, autism, multiple sclerosis, Down syndrome, dyslexia and a wide range of articulation/ phonological disorders are all characterized by the inability of the prefrontal cortex to integrate sensory input with motor output.
The medical community tends to view these disorders as heterogenous – and seemingly unsolvable. As a result, few pharmaceutical remedies have been investigated. No non-toxic pharmaceutical intervention has been approved.
Better treatment approaches are needed. Using small doses of psychostimulants whose safety record has long ago been established, Gilrose’s patented approach has been used to successfully treat ~1,000 patients suffering from severe limitations and improved the quality of their lives.
“Just because you have been told that you
have permanent brain damage does
not mean that you cannot get better.”
- Dr. Bruce Roseman, Chief Science Officer
Dr. Bruce Roseman
Co-Founder and Chief Science Officer
Dr. Bruce Roseman is a highly regarded pediatric neurologist in White Plains, NY and has been granted over 20 U.S. patents.
Career highlights:
Listed among Best Doctors in America by Castle Connelly and by Naifeh & Smith.
Co-author of articles in numerous medical journals including Lancet, Journal of Pediatrics, Pediatric Neuroscience, and Journal of the American Society of Child Psychiatry.
Peer reviewed presentations before the NIH, American Epilepsy Society, International Celiac Symposium, American Academy of Pediatrics, Child Neurology Society and other organizations.
Recipient of research grants from Columbia University and the Croll Foundation.
New York Medical Hospital – Chief of Pediatric Neurology
Columbia University – Professor of Speech & Pathology, Teacher’s College, Behavioral Sciences Dept.
Georgetown Medical School (M.D)., Johns Hopkins (Pediatric Residency). Columbia Presbyterian (Pediatric Neurology Fellowship).
Dr. Gilla Kaplan
Co-Founder and Chief Research Officer
Dr. Gilla Kaplan has had a distinguished career in medical research. She served as a member of Celgene's board of directors from 1998 until 2018.
Career highlights:
Bill and Melinda Gates Foundation - Director of the Global Health Program, Tuberculosis. International Scientific Advisory Committee.
New Jersey Medical School, The Public Health Research Institute Center, Professor of Medicine and Research Scientist.
Rockefeller University, Professor of Medicine and Research Scientist.
Recipient of multiple grants from the NIH-NIAID and other foundations.
Published over 200 original articles in peer-reviewed journals as well as monographs, book chapters, and review articles.
Howard Hughes Medical Institute - Scientific Advisory Board member
Chair of the Scientific Advisory Board of the Heiser Program for Research in Leprosy and Tuberculosis.
Chair of the Board of the Desmond Tutu HIV Foundation.
University of Tromsø (Norway) - MSc and PhD in Cellular Immunology.
Arnie Berman
Chief Business Officer
Arnie Berman has been in the investment industry for over 25 years with roles as portfolio strategist, technology stock strategist, macro-sector analyst and equity research group leader. He also served as CFO and COO of Technology Focus Capital Management and Park Avenue Value Partners.
Over the course of his career, Arnie has been a frequent guest on CNBC, CNN, PBS and Bloomberg television programs. He was also regularly quoted in Barron’s, Wall Street Journal, Forbes, Business Week, Fortune and other publications. Arnie was also a contributing editor and monthly columnist for Red Herring magazine. Mr. Berman is a Chartered Financial Analyst – and a magna cum laude graduate of Brown University with an Sc.B. in Applied Mathematics / Economics.
14 US Patents, 4 International Patents
and Over 30 Years of Patient Experience
Our work and associated patent portfolio is based on extensive observational data and quantifiable reductions in speech, language, gait and limb impairments across broad patient populations.
When administered across a diversity of manifestations, the Gilrose treatment appears to restore neural pathways extending from the prefrontal cortex, resulting in greater integration of motor planning and execution.
Gilrose’s claims are backed by extensive written and video documentation. Our methodology is easily repeatable by other parties.